Dimenhydrinate: Difference between revisions
Elcatracho (talk | contribs) |
No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: oral, IV/IM | *Routes of Administration: oral, IV/IM | ||
*Common Trade Names: | *Common Trade Names: Dramamine | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Motion Sickness=== | |||
*50mg PO/IV/IM q4-6h | *50mg PO/IV/IM q4-6h | ||
**Maximum Dose: 400 mg within 24 hours | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Motion Sickness=== | |||
*2-6yo: 12.5-25mg PO q6-8 hrs | *2-6yo: 12.5-25mg PO q6-8 hrs | ||
**Maximum Dose: 75 mg within 24 hours | |||
*6-12yo: 25-50mg PO q6-8h | *6-12yo: 25-50mg PO q6-8h | ||
**150 mg within 24 hours | |||
*1.25 mg/kg IM q6h | *1.25 mg/kg IM q6h | ||
| Line 31: | Line 36: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 5-8 hours | ||
*Metabolism: Liver | *Metabolism: Liver | ||
*Excretion: Renal | *Excretion: Renal | ||
Latest revision as of 16:56, 5 April 2023
Administration
- Type: Antiemetics; Antihistamines
- Dosage Forms:
- Routes of Administration: oral, IV/IM
- Common Trade Names: Dramamine
Adult Dosing
Motion Sickness
- 50mg PO/IV/IM q4-6h
- Maximum Dose: 400 mg within 24 hours
Pediatric Dosing
Motion Sickness
- 2-6yo: 12.5-25mg PO q6-8 hrs
- Maximum Dose: 75 mg within 24 hours
- 6-12yo: 25-50mg PO q6-8h
- 150 mg within 24 hours
- 1.25 mg/kg IM q6h
Special Populations
- Pregnancy Rating: B
- Lactation risk: Milk effects are posible
- Renal dosing:
- Hepatic dosing: consider dose reduction
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
- Nausea, vomiting
- Sedation
Pharmacology
- Half-life: 5-8 hours
- Metabolism: Liver
- Excretion: Renal
Mechanism of Action
- Precise anti-nausea mechanism unknown, has depressant action on hyperstimulated labyrinthine function
Comments
- Dimenhydrinate is a combination drug of diphenhydramine and 8-chlorotheophylline
- Used recreationally as a deliriant[1]
See Also
References
- ↑ Abuse and Misuse Potential of Dimenhydrinate: A Review of the Clinical Evidence. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; December 1, 2015.